-
公开(公告)号：US5773243A
公开(公告)日：1998-06-30
申请号：US447411
申请日：1995-05-23
摘要： DNA sequences encoding cobra C3, CVF1, and CVF2, as well as plasmids and transformed hosts comprising such DNA sequences, are provided.
摘要翻译： 提供了编码眼镜蛇C3，CVF1和CVF2的DNA序列，以及包含这种DNA序列的质粒和转化宿主。
-
公开(公告)号：US5965106A
公开(公告)日：1999-10-12
申请号：US461267
申请日：1995-06-05
申请人： Nicholas Pomato , Richard P. McCabe , Gregory A. Hawkins , Reinhard Bredehorst , Chong-Ho Kim , Carl-Wilhelm Vogel
发明人： Nicholas Pomato , Richard P. McCabe , Gregory A. Hawkins , Reinhard Bredehorst , Chong-Ho Kim , Carl-Wilhelm Vogel
IPC分类号： A61K47/48 , A61K51/10 , A61K39/395 , A61K51/00
CPC分类号： B82Y5/00 , A61K47/48746 , A61K51/1093 , A61K2121/00
摘要： A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.
摘要翻译： 一种通过施用与亲和成分偶联的靶向部分来体内靶向患者功能部分的方法，其中所述靶向部分对靶区域中的结合位点具有亲和力，以及将结合配偶体施用于与 功能部分以定位目标区域中的功能部分。 优选地，靶向部分是抗体，并且当进行体内成像或治疗时，功能部分是放射性金属。 亲和成分可以是新型甲氨蝶呤类似物。 优选地，亲和性组分是热稳定的。
-
3.发明授权S-(2-thiopyridyl)-L-cysteine, a heterobifunctional crosslinking reagent 失效S-（2-噻吩基）-L- CYSTEINE，一种异构交联试剂
公开(公告)号：US5157123A
公开(公告)日：1992-10-20
申请号：US322214
申请日：1989-03-13
IPC分类号： C07C323/59 , C07D213/71 , G01N33/543
CPC分类号： C07D213/71 , C07C323/59 , G01N33/54353
摘要： Site-specific heterobifunctional crosslinkers of the formula:X--COCH(NH.sub.2)--Y--Zwhere X is a carbonyl reactive group, Y is a variable length spacer, and Z is a thiol reactive group, are useful for the specific labelling of biomolecules or bioaffecting molecules.
摘要翻译： 具有下式的位点特异性异双功能交联剂：X-COCH（NH2）-YZ，其中X是羰基反应性基团，Y是可变长度的间隔基，Z是硫醇反应性基团，可用于生物分子或生物吸附的特异性标记 分子。
-
4.发明申请公开(公告)号：US20080234191A1
公开(公告)日：2008-09-25
申请号：US11890900
申请日：2007-08-07
CPC分类号： C07K14/472 , A61K38/00 , C07K14/463 , C07K2319/00
摘要： A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics.
摘要翻译： 公开了修饰的人补体C3蛋白（C3），其包含部分人C3蛋白的取代与眼镜蛇毒因子蛋白（CVF）的相应部分，其导致具有CVF功能的人C3蛋白，但基本上 免疫原性降低。 有利地，可以操作C3蛋白以包含以下CVF功能中的至少一种：增加C3转化酶的稳定性和增加对因子H和/或I的作用的抗性。大量含有取代的杂合C3蛋白 呈现C3的α链的C末端部分并进行上述功能的测试。 提出了治疗诸如再灌注损伤，自身免疫疾病和其他增加补体活化的疾病的方法以及增加基因治疗剂和其它治疗剂的有效性的方法。
-
公开(公告)号：US06303754B1
公开(公告)日：2001-10-16
申请号：US09017947
申请日：1998-02-03
IPC分类号： C07K14745
摘要： Recombinant proCVF exhibits substantially the same activity as CVF and is useful for lowering complement activity
摘要翻译： 重组proCVF表现出与CVF基本上相同的活性，可用于降低补体活性
-
-
7.发明授权
公开(公告)号：US5106762A
公开(公告)日：1992-04-21
申请号：US512272
申请日：1990-04-20
申请人： Reinhard Bredehorst , Frances S. Ligler , Anne W. Kusterbeck , Gregory A. Wemhoff , Carl-Wilhelm Vogel
发明人： Reinhard Bredehorst , Frances S. Ligler , Anne W. Kusterbeck , Gregory A. Wemhoff , Carl-Wilhelm Vogel
IPC分类号： C07K14/62 , G01N33/533
CPC分类号： C07K14/62 , G01N33/533
摘要： Ligand-label conjugates which are an oligopeptide of 5 to 100 amino acid residues, bonded to a ligand or receptor, which contain a plurality of chemiluminescent or fluorescent labels and a plurality of polyoxoanions of sulfur or phosphorus are useful for immunoassays. Such conjugates are hydrophilic and exhibit very low nonspecific binding, thereby significantly increasing the signal to background ratio in immunoassays.
摘要翻译： 与配体或受体结合的5至100个氨基酸残基的寡肽的配体 - 标记缀合物，其含有多个化学发光或荧光标记和多个硫或磷的多氧阴离子可用于免疫测定。 这种缀合物是亲水性的并且表现出非常低的非特异性结合，从而显着增加免疫测定中的信号与背景比。
-
公开(公告)号：US06607897B2
公开(公告)日：2003-08-19
申请号：US09925442
申请日：2001-08-10
IPC分类号： C12N1557
摘要： Recombinant proCVF exhibits substantially the same activity as CVF and is useful for lowering complement activity.
-
公开(公告)号：US5714344A
公开(公告)日：1998-02-03
申请号：US118674
申请日：1993-09-10
申请人： Markus W. Ollert , Patrick Ziegelmuller , Thomas Grunwald , Reinhard Bredehorst , Carl-Wilhelm Vogel
发明人： Markus W. Ollert , Patrick Ziegelmuller , Thomas Grunwald , Reinhard Bredehorst , Carl-Wilhelm Vogel
摘要： A novel functionally active derivative of cobra venom factor is described in which the .beta.-chain has been cleaved by treatment with a protease. Gel electrophoretic analyses of the purified derivative revealed the absence of an intact .beta.-chain and a decrease of the molecular weight.
摘要翻译： 描述了眼镜蛇毒因子的新型功能活性衍生物，其中β-链通过用蛋白酶处理而被切割。 纯化的衍生物的凝胶电泳分析显示不存在完整的β-链和分子量的降低。
-
公开(公告)号：US5433955A
公开(公告)日：1995-07-18
申请号：US134520
申请日：1993-10-08
IPC分类号： A61K31/715 , A61K47/48 , A61K38/52 , A61K31/70 , C07H15/252 , C12N11/06
CPC分类号： A61K31/70 , A61K31/715 , A61K47/48761 , B82Y5/00
摘要： A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.
摘要翻译： 使用活化剂 - 靶向部分缀合物在动物中进行体内前体药物的位点特异性体内活化的方法，以在预定的使用位点定位活化剂，以及在活化剂存在下转化为活性药物的前药化合物 。 在优选的实施方案中，靶向部分，活化剂和前药在所治疗的动物中表现出很少的或不具有免疫原性。 靶向部分对于与非靶组织的结合相对于靶组织是相对特异的。 活化剂在循环或非靶组织中没有发现或仅存在少量，不具有其在循环中或非靶组织中的活性的底物，可以连接到靶向部分，并且能够转化 该前体药物为活性药物。 选择前体药物是通过活化剂转化后在靶组织上发挥细胞毒活性的能力。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.026 秒)
